Angiotensin II receptor antagonist: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 3: | Line 3: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Angiotensin II receptor antagonists block [[angiotensin | Angiotensin II receptor antagonists block [[Angiotensin receptor|angiotensin II AT<sub>1</sub> receptors]], in contrast to [[angiotensin-converting enzyme inhibitor]]s, which block the conversion of [[angiotensin]] I to the hypertensive [[angiotensin]] II. Along with [[Angiotensin-converting enzyme inhibitor]]s, they act on the [[renin-angiotensin system]]; the two classes may be used synergisticly. | ||
==Applications== | ==Applications== | ||
Revision as of 00:59, 15 June 2008
Angiotensin II Type 1 receptor blockers (ARBs) are "agents that antagonize angiotensin II type 1 receptor. Included are angiotensin II analogs such as saralasin and biphenylimidazoles such as losartan. Some are used as antihypertensive agents."[1]
Mechanism of action
Angiotensin II receptor antagonists block angiotensin II AT1 receptors, in contrast to angiotensin-converting enzyme inhibitors, which block the conversion of angiotensin I to the hypertensive angiotensin II. Along with Angiotensin-converting enzyme inhibitors, they act on the renin-angiotensin system; the two classes may be used synergisticly.
Applications
These drugs are primarily antihypertensives. They may also be used to protect the kidneys.
Adverse effects
Angiotensin II receptor antagonists can cause hyperkalemia. The rise in potassium has been reported to be both similar to[2] and less that occurs with angiotensin-converting enzyme inhibitors.[3]
References
- ↑ Anonymous (2024), Angiotensin II Type 1 Receptor Blockers (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ The ONTARGET Investigators. 2008. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 358, no. 15:1547-1559.
- ↑ Bakris GL, Siomos M, Richardson D, et al (2000). "ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group". Kidney Int. 58 (5): 2084–92. DOI:10.1111/j.1523-1755.2000.00381.x. PMID 11044229. Research Blogging.